Lineage reports Q2 2026 results, advances COR1 corneal program and OpRegen data
Lineage highlighted three-year OpRegen data, early COR1 manufacturing progress, and a new scientific advisory board, with cash seen lasting into Q3 2028.
SEC filing
Latest
1 story